IP Library › Granted Patent US 12,534,442
Granted Patent B2
US 12,534,442 · App. 17/623,527 · Granted Jan 27, 2026

Benzisoxazole derivative

Inventors: Tomoyuki Tanaka (Osaka, JP); Yoshiaki Isobe (Osaka, JP); Hiroyuki Kitano (Osaka, JP); Hiroaki Tanaka (Osaka, JP); Shun Narai (Osaka, JP)
Assignee: Sumitomo Pharma Co., Ltd.
C07D261/20A61P25/02A61P25/14A61P25/16C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,442
App. No.
17/623,527
Granted
Jan 27, 2026
Kind
B2
Abstract

The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R 1 is hydrogen, etc., R 2 is halogen, etc., R 3 , R 4 , R 5 , and R 6 are hydrogen, etc.

Claims (134)

1 . A compound of formula (1):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy),

R 2 is halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy, and

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, cyano, nitro, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or C 1-6 alkoxy (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy).

2 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, fluorine, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), and

R 2 is fluorine, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy.

3 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, cyano, nitro, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or C 1-6 alkoxy (which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy).

4 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, fluorine, or C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy, and

R 2 is fluorine, or C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy, or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy.

5 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, or C 1-3 alkoxy which may be substituted with 1-3 fluorine.

6 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, fluorine, or C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy,

R 2 is fluorine, or C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy, or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy, and

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, or C 1-3 alkoxy which may be substituted with 1-3 fluorine.

7 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl)propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1-fluoromethane-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1,1-difluoromethane-sulfonamide,

1-(1,2-benzoxazol-3-yl)cyclopropane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)propane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)butane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1-fluoroethane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)-2-methylpropane-1-sulfonamide,

1-(5-methoxy-1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

1-(5-fluoro-1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

1-(5-chloro-1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

8 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl)propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1-fluoromethane-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1,1-difluoromethane-sulfonamide,

1-(1,2-benzoxazol-3-yl)cyclopropane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl)-1-fluoroethane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

9 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl)propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl)cyclopropane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl)ethane-1-sulfonamide.

10 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form I which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 5.7°±0.2 and 17.3°±0.2°.

12 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form of form I which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 5.7°±0.2, 14.1±0.2°, 17.3°±0.2°, 19.1°±0.2°, 19.3±0.2°, 21.6°±0.2°, 22.5±0.2°, 23.1°±0.2°, 23.3°±0.2°, and 26.5°±0.2°.

13 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form of form II which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 8.7°±0.2° and 17.6°±0.2°.

14 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form of form II which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 8.7°±0.2°, 13.5°±0.2°, 15.5°±0.2°, 17.6°±0.2°, 20.3°±0.2°, 21.6°±0.2°, 22.6°=0.2°, 26.2°±0.2°, 26.8°±0.2°, and 35.2°±0.2°.

15 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form of form III which is characterized by a powder x-ray diffraction pattern having diffraction angle (2θ°) peaks of 11.1°±0.2° and 20.3°±0.2°.

16 . The compound of claim 1 which is (1R)-1-(1,2-Benzoxazol-3-yl) ethane-1-sulfonamide in crystalline form of form III which is characterized by a powder x-ray diffraction pattern having four or more diffraction angle (2θ°) peaks selected from 11.1°±0.2°, 13.8°±0.2°, 17.0°±0.2°, 20.3°±0.2°, 21.4°±0.2°, 22.1°±0.2°, 22.4°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.9°±0.2°.

17 . A Compound of formula (1):

or pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen or C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy,

R 2 is C 1-6 alkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, and C 1-3 alkoxy, or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl which may be substituted with 1-3 substituents selected independently from the group consisting of fluorine, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy, and

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, or C 1-6 alkoxy (which may be substituted with 1-3 fluorine).

18 . A Compound of formula (1):

or pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen or C 1-6 alkyl,

R 2 is C 1-6 alkyl, or

R 1 and R 2 are taken together with the carbon atom to which they are attached to form C 3-6 cycloalkyl, and

R 3 , R 4 , R 5 , and R 6 are hydrogen.

19 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen or C 1-6 alkyl,

R 2 is C 1-6 alkyl, and

R 3 , R 4 , R 5 , and R 6 are hydrogen.

20 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:

1-(1,2-benzoxazol-3-yl) ethane-1-sulfonamide,

2-(1,2-benzoxazol-3-yl) propane-2-sulfonamide,

1-(1,2-benzoxazol-3-yl) cyclopropane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl) propane-1-sulfonamide,

1-(1,2-benzoxazol-3-yl) butane-1-sulfonamide,

(1R)-1-(1,2-benzoxazol-3-yl) ethane-1-sulfonamide, or

(1S)-1-(1,2-benzoxazol-3-yl) ethane-1-sulfonamide.

21 . A method i for treating nervous system diseases or psychiatric diseases which are initiated by abnormality of T-type calcium channel, comprising administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof as an active ingredient.

22 . The method of claim 21 , wherein the nervous system diseases or psychiatric diseases which are initiated by abnormality of T-type calcium channel are selected from epilepsy, seizure disorder, motor dysfunction, movement disorder, parkinsonism, episodic and drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, dementia with Lewy body, cerebellar ataxia, parkinsonism-ALS dementia complex, basal ganglia calcification, levodopa-induced dyskinesia in Parkinson's disease, drug-induced dyskinesia, nociceptive pain, neuropathic pain, chemotherapy-induced peripheral neuropathy, phantom pain, central pain, pain associated with Guillain-Barre syndrome, pain associated with multiple sclerosis, pain associated with Parkinson's disease, hyperalgesia or allodynia associated with neuropathic pain, fatigue, migraine, schizophrenia, autism, Gilles de la Tourette syndrome, bipolar disorder, depressive disorder, anxiety, sleep disorder, cardiac arrhythmia, hypertension, cancer, diabetes, infertility, and sexual dysfunction.

23 . The method of claim 21 , wherein the nervous system diseases or psychiatric diseases which are initiated by abnormality of T-type calcium channel are selected from Parkinson's disease, levodopa-induced dyskinesia in Parkinson's disease, essential tremor, anxiety, neuropathic pain, chemotherapy-induced peripheral neuropathy, phantom pain, central pain, pain associated with Guillain-Barre syndrome, pain associated with multiple sclerosis, pain associated with Parkinson's disease, and hyperalgesia or allodynia associated with neuropathic pain.

24 . The method of claim 21 , wherein the nervous system diseases or psychiatric diseases which are initiated by abnormality of T-type calcium channel are selected from Parkinson's disease, essential tremor, and chemotherapy-induced peripheral neuropathy.

25 . A method for treating nervous system diseases or psychiatric diseases which are initiated by abnormality of T-type calcium channel, comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof to a patient in need thereof.

26 . A method for treating a disease associated with abnormality of T-type calcium channel, comprising administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is used in combination with at least one drug selected from the drug-group classified as drugs for treating Parkinson's disease, drugs for treating essential tremor, or drugs for treating neuropathic pain.

27 . A method for treating nervous system disease or psychiatric disease, comprising administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is used in combination with at least one drug selected from the drug-group classified as drugs for treating Parkinson's disease, drugs for treating essential tremor, or drugs for treating neuropathic pain.

28 . A process for preparing a compound of formula (2):

or a pharmaceutically acceptable salt thereof, wherein

R 1A is hydrogen, halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy),

R 2A is halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), provided that R 1A and R 2A are different, and

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, cyano, nitro, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or C 1-6 alkoxy (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy),

which comprises Steps 1 to 3 below,

(Step 1) reacting a compound of formula (3):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , and R 6 are as defined above, and

a compound of formula (4a) or (4b):

R 7 —SH  (4a)

R 7 —S—S—R 7   (4b)

or a salt thereof, wherein R 7 is a leaving group selected from 2-(methoxycarbonyl)ethyl, mesitylenecarbonyloxymethyl, 2-benzothiazolyl (the benzene ring of which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 1-6 alkoxy (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), hydroxy, cyano, nitro, amino (which may be substituted with 1-2 C 1-3 alkyl), carboxylic acid, carbamoyl (the amino moiety of which may be substituted with 1-2 C 1-3 alkyl), and C 1-6 alkoxycarbonyl), 2-pyridyl, 2-pyrimidinyl, or 2-(trimethylsilyl)ethyl, which can release a sulfinic acid salt in the reaction

to prepare a compound of formula (5):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above,

(Step 2) oxidizing the compound of formula (5) or a salt thereof to prepare a compound of formula (6):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above, and

(Step 3) removing R 7 from the compound of formula (6) or a salt thereof and sulfonamidating the site to prepare the compound of formula (2) or a pharmaceutically acceptable salt thereof.

29 . The process of claim 28 , which further comprises the following step;

(Step 4a) optically-selectively hydrolyzing a compound of formula (7):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , and R 6 are as defined in claim 21 , and R 8 is C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 1-6 alkoxy, or C 1-6 alkylcarbonyloxymethoxy,

with a hydrolase selected from lipase, esterase, amidase, or protease to prepare the compound of formula (3).

30 . The process of claim 28 , wherein R 1A is hydrogen, which further comprises the following step;

(Step 4b) optically-selectively reducing a compound of formula (8):

or a salt thereof,

with reductase and a coenzyme selected from NADH or NADPH to prepare the compound of formula (3).

31 . The process of claim 28 , wherein R 7 is 2-benzothiazolyl.

32 . The process of claim 29 , wherein R 8 is methyl, and the hydrolase is lipase.

33 . The process of claim 30 , wherein R 2A is methyl, and the reductase is carbonyl reductase or alcohol dehydrogenase.

34 . A process for preparing a compound of formula (2):

or a pharmaceutically acceptable salt thereof, wherein

R 1A is hydrogen, halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy),

R 2A is halogen, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), or C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), provided that R 1A and R 2A are different, and

R 3 , R 4 , R 5 , and R 6 are the same or different and are hydrogen, halogen, cyano, nitro, C 1-6 alkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy), C 3-6 cycloalkyl (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 1-3 alkyl, and C 1-3 alkoxy), or C 1-6 alkoxy (which may be substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, C 3-6 cycloalkyl, and C 1-3 alkoxy),

which comprises Steps 1 to 2 below,

(Step 1) reacting a compound of formula (9):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , and R 6 are as defined above, and X 1A is halogen, and

an optically-active compound of formula (10):

or a salt thereof, wherein P 1A is 2-indanol-1-yl, 2-phenylethan-1-ol-2-yl, or 3-methylbutan-1-ol-2-yl, P 2A is hydrogen or benzyl (the benzene ring of which may be substituted with 1-5 substituents selected independently from the group consisting of halogen, C 1-6 alkyl, and C 1-6 alkoxy, and

dividing the prepared diastereomers to prepare a compound of formula (11):

or a salt thereof, wherein R 1A , R 2A , R 3 , R 4 , R 5 , R 6 , P 1A , and P 2A are as defined above, and

(Step 2) deprotecting the compound of formula (11) or a salt thereof to prepare the compound of formula (2) or a pharmaceutically acceptable salt thereof.

35 . The process of claim 34 , wherein R 1A is hydrogen, and R 2A is methyl.

36 . The process of claim 34 , wherein P 1A is 2-indanol-1-yl, and P 2A is hydrogen.

Assignments (2)
CHANGE OF NAME Recorded Jun 10, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060161/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2022
From: TANAKA, TOMOYUKI; ISOBE, YOSHIAKI; KITANO, HIROYUKI; TANAKA, HIROAKI; NARAI, SHUN
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 059062/0655 →
Priority Claims (1)
JP 2020-117236 · Jul 7, 2020 · national
Continuity (1)
Related Publication 20230202991A1 · Jun 29, 2023
References Cited (147)
US 4172896A · Uno · 1979 [cited by applicant]
US 6342515B1 · Masuda et al. · 2002 [cited by applicant]
US 20180271838A1 · Ohno · 2018 [cited by applicant]
CN 106810507A · 2017 [cited by applicant]
JP 5377057 · 1978 [cited by applicant]
JP 37226 · 1991 [cited by applicant]
WO WO9413665 · 1994 [cited by applicant]
WO WO9933465 · 1999 [cited by applicant]
WO WO0119321A2 · 2001 [cited by applicant]
Patani et al., Chem. Rev., 1996, ACS, vol. 96, pp. 3147-3176 (Year: 1996). [cited by examiner]
International Preliminary Report on Patentability and Written Opinion issued Jan. 10, 2023 in PCT/JP2021/025403, 5 pages. [cited by applicant]
Kenji Shirakura et al., “Therapeutic Agent for Levodopa-Activated Parkinson's Disease Zonisamide (Trerief® tablets)”, Journal of Japanese Society of Hospital Pharmacists (Jun. 1, 2009), vol. 45, No. 6, pp. 830-831 with … [cited by applicant]
Shunji Touya et al., “Therapeutic Effects of Zonisamide on DLB Parkinsonism: Subpopulation Analysis for Data from Two Studies”, Clinical Neurology (0009-918X) vol. 59 Suppl. p. S300 (Nov. 2019). [cited by applicant]
Kentaro Takai et al., “Safety of Long-Term Zonisamide Administration (25 mg per day) to DLB Patients: Post Hoc Analysis for Phase III Study”, Clinical Neurology (0009-918X) vol. 59 Suppl. p. S300 (Nov. 2019). [cited by applicant]
Masaaki Tagawa et al., “Efficacy of Long-Term Zonisamide Administration (25 mg per day) to DLB Patients: Post Hoc Analysis for Phase III Study (2)”, Clinical Neurology (0009-918X) vol. 59 Suppl. p. S299(Nov. 2019). [cited by applicant]
Shunji Touya et al.,“Therapeutic Effect of Zonisamide against DLB Parkinsonism: Subpopulation Analysis on Data Compiled from Two Studies”, Dementia Japan(1342-646X) vol. 33 No. 4 p. 528(Oct. 2019). [cited by applicant]
Hidenori Maruyama et al., “Zonisamide Plays a Beneficial Role in Improving Parkinsonism by Cognitive Function and BPSD Severity Level in DLB Patients: Comprehensive Analysis”, Dementia Japan(1342-646X) vol. 33 No. 4 p. … [cited by applicant]
Osamu Konishi et al., “Therapeutic Effects of Zonisamide against DLB Parkinsonism by Cognitive Function or BPSD severity: Subpopulation Analysis on Data Compiled from Two Studies”, Program and Abstracts of the Congress … [cited by applicant]
Shunji Toya et al., “Therapeutic Effect of Zonisamide against DLB Parkinsonism in Stratified Patient Population: Subpopulation Analysis on Data Compiled from Two Studies”, Program and Abstracts of the Congress of Parkin… [cited by applicant]
Hidenori Maruyama et al., “Therapeutic Effect of Zonisamide against DLB Parkinsonism in Stratified Patient Population: Subpopulation Analysis on Data Compiled from Two Studies (Part 2)”, Japanese Journal of Geriatric Ps… [cited by applicant]
Masaaki Tagawa et al., “Efficacy of Long-Term Zonisamide Administration (25 mg per day) to DLB Patients: Post Hoc Analysis for Phase III Study (Part 2)”, Japanese Journal of Geriatric Psychiatry (0915-6305) vol. 30, Spe… [cited by applicant]
Osamu Konishi et al., “Safety of Long-Term Zonisamide Administration (25 mg per day) to DLB Patients: Post Hoc Analysis for Phase III Study (Part 1)”, Japanese Journal of Geriatric Psychiatry (0915-6305) vol. 30 Special… [cited by applicant]
Hidenori Maruyama et al., “Zonisamide's Effects on Each of Motor Symptoms in DLB Patients: Pooled Analysis for Phase II and III Studies”, Dementia Japan(1342-646X) vol. 32, No. 3, p. 478 (Sep. 2018). [cited by applicant]
Shunji Toya et al., “Assessment on Efficacy of Zonisamide upon Long-Term Administration to DLB Patients with Dyskinesia”, Program and Abstracts of the Congress of Parkinson's Disease and Movement Disorders vol. 12, p. 1… [cited by applicant]
Kentaro Takai et al., “Efficacy of Zonisamide on Motor Symptoms of Lewy Body Dementia: Additional Analysis for Phase III Study”, Program and Abstracts of the Congress of Parkinson's Disease and Movement Disorder vol. 12… [cited by applicant]
Hidenori Maruyama et al., “Additional Analysis for Zonisamide DLB Phase II Study (Part 1): Effects on Motor Symptoms”, Japanese Journal of Geriatric Psychiatry (0915-6305) vol. 28, Special Issue II, p. 206 (Jun. 2017). [cited by applicant]
Hidenori Maruyama et al., “Effects of Zonisamide on Core Symptoms of Lewy Body Dementia: Additional Analysis for Phase II DLB Study”, Clinical Neurology (0009-918X) vol. 56 Suppl. p. S401(Dec. 2016). [cited by applicant]
Yoshiki Miura et al., “Current Research Findings for Unique Antiepileptic Drugs, Zonisamide and Clobazam”, Medical Science Digest(1347-4340) vol. 33 No. 4, p. 803-806(Apr. 2007). [cited by applicant]
Yoshinobu Masuda, et al., “The novel anticonvulsant zonisamide prevents dopaninergic neurodegeneration induced by MPTP”, The Japanese Journal of Pharmacology(0021-5198) vol. 76 Suppl.| p. 119P (Apr. 1998). [cited by applicant]
Masanao Shimizu et al., “Research and Development of Zonisamide, a New Type of Antiepileptic Drug”, Yakugaku Zasshi (0031-6903) vol. 116 (7) p. 533-547 (Jul. 1996). [cited by applicant]
Yoshinobu Masuda, et al., “All About Zonisamide”, The Pharmaceutical Society of Japan (0918-9823) vol. 111 No. 1, p. 136-137(Mar. 1991). [cited by applicant]
Tadahiko Karasawa et al., “Anticonvulsant AD-810”, Annual Meeting Abstracts of the Pharmaceutical Society of Japan (0918-9823) vol. 104, p. 507 (Mar. 1984). [cited by applicant]
Kenji Onodera et al., “Usefulness of Animal Models for Osteoporosis with Antiepileptic Drugs”, Folia Pharmacologica Japonica 127(5): 375-380, 2006. [cited by applicant]
Miho Murata et al., “Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial”, Parkinsonism and Related Disorders(1353-8020) vol. 76, p. 91-97 (2020). [cited by applicant]
Kazuko Hasegawa et al., “Zonisamide's Efficacy and Safety in DLB Patients with Parkinsonism: Pooled Analysis for Phase II and III Studies”, Program and Abstracts of the Congress of Parkinson's Disease and Movement Disor… [cited by applicant]
Toshinari Odawara et al., “Review on Efficacy and Safety of Zonisamide on Dyskinesia in DLB Patients (Phase III Study)”, Japanese Society of General Hospital Psychiatry (0915-5872) vol. 31, Supplement, p. S.253, (Nov. 2… [cited by applicant]
Kazuko Hasegawa et al., “Zonisamide Plays a Beneficial Role in Improving Parkinsonism by Cognitive Function and BPSD Severity Level in DLB Patients: Comprehensive Analysis”, Program and Abstracts for Academic Conference… [cited by applicant]
Toshinari Odawara et al., “Verification on Efficacy and Safety of Zonisamide on Dyskinesia in DLB Patients (Phase III Study)”, Psychiatria et Neurologia Japonica / The 115th Annual Meeting of the Japanese Society of Psy… [cited by applicant]
Toshinari Odawara et al., “Ameliorating Effect of Zonisamide against Parkinsonism in DLP Patients Stratified by Severity: Subpopulation Analysis on Data Compiled from Two Studies (Part 1)”, Japanese Journal of Geriatric… [cited by applicant]
Toshinari Odawara et al., “Review on Efficacy of Zonisamide upon Long-Term Administration to DLB Patients with Dyskinesia”, Japanese Journal of Geriatric Psychiatry (0915-6305), vol. 29 Special Issue II, p. 201(Jun. 1, … [cited by applicant]
Toshinari Odawara et al., “Review on Efficacy and Safety of Zonisamide in DLB Patients with Dyskinesia (Long-Term Administration)”, Dementia Japan (1342-646X) vol. 32 No. 3 p. 478 (Sep. 15, 2018). [cited by applicant]
Miho Murata et al., “Study on Long-term Zonisamide Therapy for DLB Patients with Dyskinesia (Phase III Study)”, Program and Abstracts for Academic Conference of Societas Neurologica Japonica vol. 58 separate vol. p. 463… [cited by applicant]
Miho Murata et al., “Zonisamide Plays a Critical Role on Improvement in DLB Patients with Dyskinesia: Placebo-Controlled, Randomized, Double-Blind Study (Phase III Study)”, Program and Abstracts of the Congress of Parki… [cited by applicant]
Toshinari Odawara et al., “Zonisamide Improves DLB Parkinsonism: A Randomized Phase 3 Study”, Dementia Japan (1342-646X) vol. 31, No. 4 p. 585 (Oct. 15, 2017). [cited by applicant]
Toshinari Odawara et al., “Effects of Zonisamide on Dyskinesia in Lewy Body Dementia Patients and on Psychiatric Symptoms: Outcomes of Randomized, Double-Blind, Placebo-Controlled Study (Phase II Study)”, Japanese Journ… [cited by applicant]
Toshinari Odawara et al., “Additional Analysis for Zonisamide DLB Phase II Study (Part 2): Effects on Cognitive Symptoms”, Japanese Journal of Geriatric Psychiatry (0915-6305) vol. 28 Special Issue II, p. 206 (Jun. 1, 2… [cited by applicant]
Toshinari Odawara et al., Effects of Zonisamide on Cognitive Functions and BPSD in Lewy Body Dementia Patients: Additional Analysis for DLB Phase II Study, Dementia Japan (1342-646X) vol. 30 No. 4 p. 577 (Oct. 15, 2016). [cited by applicant]
Miho Murata et al., “A Placebo-Controlled Exploratory Study of Zonisamide for Parkinsonism in DLB”, Annual Meetings of the Japanese Society of Neurology, Program and Proceedings vol. 55 separate volume p. 339 (2015). [cited by applicant]
Jun Takehara et al., “Development of the Modern Japanese Pharmaceutical Industry, Part 17 Antiepileptic Drugs of Pharmaceutical Companies in Japan”, The 122nd Pharmaceutical Society of Japan (0918-9823) No. 3 p. 194 (Ma… [cited by applicant]
Masanao Shimizu et al., “Development and study of novel anti-epileptic drug “Zonisamide””, The Pharmaceuticals monthly, vol. 38, No. 7 p. 1721-1725 (Jun. 1996) (0016-5980). [cited by applicant]
Takashi Mimaki et al., “[ [cited by applicant]
Takashi Mimaki et al., “Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain”, Medical Journal of Osaka University (0030-6169) p. 13-17 (Mar. 1990). [cited by applicant]
Atsuhiro Fukuda et al., “Cerebral Protective Action of Zonisamide and Clinical Experience on Neurosurgical Patients”, Japanese Pharmacology & Therapeutics (0386-3603) vol. 19, No. 5, p. 2011-2018 (May 1991). [cited by applicant]
Yoshinobu Masuda, “Special issue : from “the 111th annual Meeting of Pharmaceutical Soc. of Japan”. Ondrug development. from the viewpoint of a pharmaclolgy researcher.On zonisamide”, The Pharmaceuticals monthly (0016-5… [cited by applicant]
Katashi Matsumoto et al., “Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction”, Chemical and Pharmaceutical Bulletin (0009-2363) vol. 37 No. 10 p. 2807-2810 (Jan. 1989). [cited by applicant]
K. Nakatsuji et al., “General pharmacology of the novel antiepileptic compound zonisamide. 2nd Communication. Effects on cardiovascular, visceral, renal and blood functions”, Arzneimittel-Forschung (0004-4172) vol. 37 N… [cited by applicant]
M. Hori et al., “General pharmacology of the novel antiepileptic compound zonisamide. 1st Communication. Effects on central nervous system”, Arzneimittel-Forschung (0004-4172) vol. 37 No. 10 p. 1124-1130 (1987). [cited by applicant]
K. Kitani et al., “Increasing anticonvulsant effect of AD-810(zonisamide) in aging BDF1 mice”, Life Sciences (1339-1344) vol. 41No. 11 p. 1339-1344 (Sep. 14, 1987). [cited by applicant]
Masahiko Suzuki, et al., “Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database”, eNeurologicalSci 20 (2020) 100257; pp. 1-7. [cited by applicant]
Theresa A. Zesiewicz, MD, et al., “A Double-Blind Placebo-Controlled Trial of Zonisemide (Zonegran) in the Treatment of Essential Tremor; [cited by applicant]
William G. Ondo, MD; “Zonisamide for Essential Tremor”; Clinical Neuropharmacolog, vol. 30, No. 6 Nov.-Dec. 2007; pp. 345-349. [cited by applicant]
Shuhei Morita, et al., “Effect of zonisamide on essential tremor: a pilot crossover study in comparison with protinolol”; Parkinsonism and Related Disorders 11 (2005) 101-103. [cited by applicant]
Adrian Handforth, MD, et al; “Zonsiamide for Essential Tremor: An Evaluator-Blinded Study”; Movement Disorders, vol. 24, No. 3, 2009; pp. 437-440.. [cited by applicant]
PCTISA210 International Search Report, Aug. 10, 2021. [cited by applicant]
Perchalski, R.J. et al., “Biotransformation and excretion: metabolite identification: other mass spectrometric methods”, Journal of Clinical Pharmacology, 1986, vol. 26, No. 6, pp. 435-442. English Translation. [cited by applicant]
Database Registry, 2014, RN 1596612-84-8. Retrieved from STN international [online]; retrieved on Jul. 26, 2021. [cited by applicant]
Suzuki, S. et al., “Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex”, Epilepsy Research, 1992, vol. 12, No. 1pp. 21-27. English Translation. [cited by applicant]
William A. Catterall et al., “International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels”, Pharmacological Reviews 57(4) 397-409 (2005). [cited by applicant]
Joseph G.McGivern et al., “Targeting N-type and T-type calcium channels for the treatment of pain”, Drug Discovery Today 11(5/6) 245-253 (2006). [cited by applicant]
Evanthia Nanou et al., “Calcium Channels, Synaptic Plasticity, and Neuropsychiatric Disease”, Neuron 98(3) 466-481 (2018). [cited by applicant]
Q. Ashton Acton, PhD. (Eds.), Ion Channels—Advances in Research and Application. 2013 Edition ScholarlyEditions™, Atlanta, Georgia, pp. 1-103. [cited by applicant]
Ryo Fukumoto et al., “Two Epilepsy Patients who Developed Renal/Ureteral Stones While Taking Topiramate (Topina®)”, Acta Urologica Japonica (2011), 57(3): 125-128. W/English Translation. [cited by applicant]
Hidenori Maruyama et al., Influences of switching from dopamine agonist to zonisamide on psychotic and motor symptoms of PD patients with hallucination and delusion, Parkinson's Disease and Movement Disorder Congress, P… [cited by applicant]
Shunsuke Tani et al., “The situation of real clinical prescription for patients with Parkinson's disease exhibiting wearing-off, and the examination of safety and effectivity of 50 mg/day of zonisamide” Neurology(ISSN:2… [cited by applicant]
Masaaki Tagawa, “Zonisamide as a repositioned drug: Fruit of serendipity”, Journal of Pharmacological Sciences(ISSN:1347-8613) vol. 133, 3Suppl. p. S80(Mar. 2017). [cited by applicant]
Chiaki Migihashi et al., “Interim report of research for achievement of specific use of zonisamide for Parkinson's disease patients (50 mg long-term)”, Parkinson's Disease and Movement Disorder Congress, Program and Pro… [cited by applicant]
Chiaki Migisashi et al., Study of safety and efficacy of 50 mg of zonisamide for Parkinson's disease patients with expression of wearing-off phenomenon—Interim report of specific use achievement research regarding long-… [cited by applicant]
Nami Kawaguchi et al., “Zonisamide (TRERIEF® tablet 25 mg) specific use achievement research targeted at Parkinson's disease patients—Research related to long-term use”, Pharma Medica(ISSN:0289-5803), vol. 32, No. 7, p.… [cited by applicant]
Yutaka Murahashi et al.,“Regarding Parkinson's disease therapeutic drug TRERIEF® (zonisamide)”, separate vol. Bio Clinica: vol. 3, No. 1 p. 150-155(May 2014). W/English Translation. [cited by applicant]
Kenji Shirakura, “Parkinson's disease therapeutic agent TRERIEF—Additional dose against wearing-off phenomenon-”, Medical Science Digest(ISSN:1347-4340), vol. 40(1) p. 42-46(Jan. 2014).—With English Translation. [cited by applicant]
Tomoaki Matsumoto et al., “Concerning New Parkinson's Therapeutic Agent “TRERIEF®””, Bio Clinica(ISSN:0919-8237), vol. 26, No. 8, p. 716-720(Aug. 2011).—with English Translation. [cited by applicant]
Tomoaki Matsumoto et al., “Anti-Parkinson Effects of Trerief®”, Sumitomo Kagaku(Issn:0387-1312) vol. 2010-II p. 62-66(Nov. 2010)—with English Translation. [cited by applicant]
Kenji Shirakura. “New anti-Parkinson's disease drug TRERIEF® (zonisamide)”, Medical Science Digest(ISSN:1347-4340), vol. 36(14) p. 1203-1206(Dec. 2010).—with English Translation. [cited by applicant]
Kenji Shirakura et al., “New Drug Prospects 2010 Part II Featured new drug Levodopa incorporation-type Parkinson's disease therapeutic drug General name: Zonisamide TRERIEF® tablet”, Medicine and drug journal(ISSN:0287-… [cited by applicant]
Kenji Shirakura, “World Medicine from Japan (34) Levodopa incorporation-type Parkinson's disease therapeutic drug TREREIF® development story”, IRYO(ISSN:0021-1699) vol. 63, No. 10, p. 680-682(Oct. 2009).—With English Tr… [cited by applicant]
Kenji Shirakura, “Levodopa incorporation-type Parkinson's disease therapy drug Zonisamide tablet (TRERIEF® tablet)”, Journal of the Chiba Pharmaceutical Association, vol. 55, No. 10 p. 960-963(Oct. 2009). [cited by applicant]
Kenji Shirakura et al., “[Introduction of new medicine] Levodopa incorporation-type Parkinson's disease therapeutic drug Zonisamide (TRERIEF® tablet)”, Journal of Japanese Society of Hospital Pharmacists (ISSN:1341-8815… [cited by applicant]
Saori Tsujii, “Protective effect of zonisamide on endoplasmic reticulum stress-induced nerve cell death”, The regional meeting of The Japanese Pharmacological Society (Nippon Yakurigaku Zasshi) 142(5): 10-10, 2013. w/ E… [cited by applicant]
Yoshio Tsuboi et al., “Zonisamide improves wearing-off without worsening dyskinesia of Parkinson's disease patients: Post hoc analysis of clinical trial data”, Parkinson's Disease and Movement Disorder Congress, Program… [cited by applicant]
Takashi ABE et al.“Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease,”, Clinical Neurology(Web) (2021) vol. 61, No. 7, pp. 449-455(J-STAGE). [cited by applicant]
Hidenori Maruyama et al., “Zonisamide improves wearing off without worsening dyskinesia of PD: post hoc analysis of clinical trial data”, Annual Meetings of the Japanese Society of Neurology, Program and Proceedings (20… [cited by applicant]
Takashi Abe et al., “Influences of shifting from dopamine agonist to zonisamide on mental and motor conditions of PD patients”, Annual Meetings of the Japanese Society of Neurology, Program and Proceedings (2020), vol. … [cited by applicant]
Hirotaka Iwaki et al., “Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms”, Journal of the Neurological Sciences(2019), vol. 402, pp. 14… [cited by applicant]
Chiaki Migihashi et al., “Evaluation of Safety and Efficacy of Zonisamide 50 mg in Parkinson's Disease Patients with Wearing-off Phenomenon—Interim Reports of the Long Term Special Drug Use Result Survey”, Journal of Ne… [cited by applicant]
Miho Murata et al., “Consolidated Analysis of Placebo-Controlled Double-Blind Study of Zonisamide in Parkinson's Patients”, Annual Meetings of the Japanese Society of Neurology, Program and Proceedings, (2014) vol. 55, … [cited by applicant]
Miho Murata et al., “Effect of Zonisamide in Shortening the Off Period: A Domestic Multicenter Joint Double-Blind Study”, Parkinson's Disease and Movement Disorder Congress, Program and Proceedings, (2013) vol. 7, pp. 7… [cited by applicant]
Masuda Y. et al., “Evidence against a Significant Implication of Carbonic Andydrase Inhibitory Activity of Zonisamide in its Anticonvulsive Effects”, Arzneimittel-Forschung, (Mar. 1994) vol. 44, No. 3, pp. 267-269. [cited by applicant]
Masuda Y. et al., “Inhibitory Effect of Zonisamide on Human Carbonic Anhydrase in vitro”, Arzneimittel-Forschung, (Apr. 1993) vol. 43, No. 4, pp. 416-417. [cited by applicant]
Tanaka, Tomoyuki, et al. “N-alkyl-[1, 1′-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate”, Bioorganic and Medicinal Chemistry Letters… [cited by applicant]
Matsumoto K. et al., “Binding of sulfonamides to erythrocytes and their components”, Chemical and Pharmaceutical Bulletin, (Jul. 1989) vol. 37, No. 7, pp. 1913-1915. [cited by applicant]
Tsuboi, Yoshio et al.,“Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials”, Journal of the Neurological Sciences, (Nov. 15, 2… [cited by applicant]
Odawara, Toshinari, et al., “Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.”, … [cited by applicant]
Hasegawa, Kazuko, et al., “Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials”, Journal of Alzheimer… [cited by applicant]
Tanaka, Tomoyuki et al., “Identification of 2-(2′-fluoro-[1,1′-biphenyl]-2-yl)acetamide as a Sodium Valproate-like broad spectrum anti-epileptic drug candidate”, Bioorganic and Medicinal Chemistry Letters, (Jan. 15, 201… [cited by applicant]
Takai, Kentaro et al., “Long-term Efficacy of Zonisamide on Parkinsonism in Dementia with Lewy Bodies: A Post-hoc Analysis of Phase 3 Trial”, Neurology, (Apr. 9, 2019) vol. 92, No. 15, Suppl. S, pp. P4.1-012. Meeting In… [cited by applicant]
Nishimaki, Takuya et al., “Long-term efficacy of zonisamide on parkinsonism in dementia with Lewy bodies: A post-hoc analysis of phase III trial”, Journal of Parkinson's Disease, (2019) vol. 9, No. 1, pp. 158. Abstract … [cited by applicant]
Toya, Shunji et al., “Long-term efficacy for parkinsonism and safety of zonisamide in patients with dementia with Lewy bodies: A phase III trial”, Journal of Parkinson's Disease, (2019) vol. 9, No. 1, pp. 162. Abstract … [cited by applicant]
Toya, Shunji et al., “Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients with Dementia with Lewy Bodies: A Phase III Trial”, Neurology, (Apr. 9, 2019) vol. 92, No. 15, Suppl. S, pp. P4.1-011. Meeti… [cited by applicant]
Nomoto, M. et al., “Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms”, Journal of the Neurological Sciences, (Oct. 15, 2019) vol. 405, … [cited by applicant]
Hasegawa, K. et al., “Zonisamide improves Parkinsonism in dementia with lewy bodies (DLB): A randomized double-blind Placebocontrolled phase 3 study” , Parkinsonism and Related Disorders, (Jan. 2018) vol. 46, Supp. Supp… [cited by applicant]
Murata, Miho et al., “Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study”, Neurology, (Feb. 20, 2018) vol. 90, No. 8, pp. e664-e672. E-ISSN: 1526-632X. [cited by applicant]
Nishimura, Yuhei et al., “Overcoming obstacles to drug repositioning in Japan”, Frontiers in Pharmacology, (Oct. 11, 2017) vol. 8, No. OCT. arn. 729.Refs: 53 E-ISSN: 1663-9812. [cited by applicant]
Tanaka, Tomoyuki et al., “Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models”, Bioorganic and Medicinal Chemistry Letters, (2017) vol. 27, No. 1, pp. 94-97. Refs: 13… [cited by applicant]
Miyauchi, M. et al., “The effect of zonisamide on abnormal muscle tone during REM sleep in a mouse model of REM sleep behavior disorder”, .Sleep Medicine, (Dec. 2017) vol. 40, Supp. Supplement 1, pp. e229.Abstract No. B… [cited by applicant]
Murata, M. et al., “Zonisamide improves DLB parkinsonism: A randomized double-blind placebo-controlled phase 3 study”, Journal of the Neurological Sciences, (Oct. 2017) vol. 381, Supp. Supplement 1, pp. 185-186. Abstrac… [cited by applicant]
Odawara, T. et al., “Influence of zonisamide on cognition and BPSD of dementia with lewy bodies :A post-hoc analysis of dementia with Lewy bodies PH2 study”, Neurodegenerative Diseases, (2017) vol. 17, Supp. Supplement … [cited by applicant]
Murata, Miho et al., “Randomized placebo-controlled trial of zonisamide in patients with Parkinson's disease”, Neurology and Clinical Neuroscience, (Jan. 1, 2016) vol. 4, No. 1, pp. 10-15. Refs: 14 E-ISSN: 2049-4173. [cited by applicant]
Odawara, Toshinari et al., “Zonisamide improves parkinsonism without psychiatric deterioration in patients with DLB: A double-blind randomized placebo-controlled study”, . American Journal of Geriatric Psychiatry, (Mar.… [cited by applicant]
Tanaka, Tomoyuki et al., “Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect”, Bioorganic and Medicinal Chemistry Letters, (Jul. 22, 2015) vol.… [cited by applicant]
Murata, Miho et al., “Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study”, Movement Disorders, (Sep. 1, 2015) vol. 30, No. 10, pp. 1343-1350. Refs: 28 ISSN: 0885-3185; E-ISSN: 1531-… [cited by applicant]
Zhu, Gang et al., “Rats harboring S284L Chrna4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype”, . Journal of Neuroscience, (Nov. … [cited by applicant]
Kaminski P et al., “Development of a fluorescence polarization immunoassay for zonisamide” Clinical Chemistry, (Jun. 2003) vol. 49, No. 6, Part 2, Supp. [S], pp. A122-A122. ISSN: 0009-9147. [cited by applicant]
Miura, Yoshiki et al., “Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats”, Epilepsy Research, (2002) vol. 49, No. 3, pp. 189-202. Refs: 34 ISSN: 0920-1211 CO… [cited by applicant]
Someya T et al., “Establishment of enzyme immunoassay for measuring serum sultopride levels” Ther.Drug Monit. (23, No. 3, 277-81, 2001) 5 Fig. 1 Tab. 13 Ref.ODEN: TDMODV ISSN: 0163-4356. [cited by applicant]
Akaike K. et al., “Regional accumulation of 14C-zonisamide in rat brain during kainic acid-induced limbic seizures”, Epilepsia (41, Suppl. 7, 37, 2000) CODEN: EPILAK ISSN: 0013-9580. [cited by applicant]
Amano S. et al., “Effects of antiepileptics on two different types of seizures in a novel epileptic mutant rat (Ihara's genetically epileptic rat: IGER)”, Epilepsia (40, Suppl. 2, 132, 1999) CODEN: EPILAK ISSN: 0013-958… [cited by applicant]
Miura Y et al., “Effects of antiepileptics on two different types of seizures in a novel epileptic mutant rat (IGER)”, Jpn.J.Pharmacol. (79, Suppl. 1, 228P, 1999) CODEN: JJPAAZ ISSN: 0021-5198. [cited by applicant]
Masuda, Yoshinobu et al., “Zonisamide: Pharmacology and clinical efficacy in epilepsy”, CNS Drug Reviews, (Winter 1998) vol. 4, No. 4, pp. 341-360. Refs: 110 ISSN: 1080-563X CODEN: CDREFB. [cited by applicant]
Masuda Y. et al., “The novel anticonvulsant zonisamide prevents dopaminergic neurodegeneration induced by MPTP”, Jpn.J.Pharmacol. (76, Suppl. I, 119P, 1998) CODEN: JJPAAZ ISSN: 0021-5198. [cited by applicant]
Minato, Hisao et al., “Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats”, Epilepsia, (Sep. 1997) vol. 38, No. 9,… [cited by applicant]
Buchanan, R. A. et al., “Zonisamide drug interactions”, Epilepsia, (1997) vol. 38, No. SUPPL. 8, pp. 107. print. Meeting Info.: Annual Meeting of the American Epilepsy Society Boston, Massachusetts, USA Dec. 7-10, 1997 … [cited by applicant]
Browne T R. et al., “Zonisamide efficacy in long-term studies”, Epilepsia (38, Suppl. 8, 108, 1997) CODEN: EPILAK ISSN: 0013-958. [cited by applicant]
Padgett C S et al., “Zonisamide efficacy and dose response”, Epilepsia (38, Suppl. 8, 107, 1997) CODEN: EPILAK ISSN: 0013-9580. [cited by applicant]
Mimaki T. et al., “Regional Distribution of C-14 Zonisamide in Rat-Brain”, Epilepsy Research, (Mar. 1994) vol. 17, No. 3, pp. 233-236.ISSN: 0920-1211. [cited by applicant]
Seino M et al., “Zonisamide”, Epilepsy Research, (1991) Supp. [3], pp. 169-174. ISSN: 0920-1211. [cited by applicant]
Kaibe, K. et al., “Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibody”, Clinical Chemistry, (1990) vol. 36, No. 1, pp. 24-27. ISSN: … [cited by applicant]
Hori, M. et al., “General pharmacology of the novel antiepileptic compound zonisamide. Part 1. Effects on central nervous system”, Arzneimittel-Forschung (Germany), (1987) vol. 37, pp. 1124-1130. 25 Refs. CODEN: ARZNAD.… [cited by applicant]
Ito, T. et al., Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats, Epilepsia, (1986) vol. 27, No. 4, pp. 367… [cited by applicant]
Uno, Hitoshi et al., “Studies on 3-substituted 1,2-benzisoxazole derivatives. VII. Catalytic reduction of 3-sulfamoylmethyl-1,2- benzisoxazole and reactions of the resulting products”, Chemical & Pharmaceutical Bulletin… [cited by applicant]
Uno, H. et al., “Syntheses of 2-sulfamoylmethylbenzoxazole derivatives and determination of their anticonvulsant activities”, Chemical and Pharmaceutical Bulletin, (1981) vol. 29, No. 8, pp. 2359-2361. ISSN: 0009-2363 C… [cited by applicant]
Kamei, C. et al., “Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats”, Archives Internationales de Pharmacodynamie… [cited by applicant]
Masuda, Y et al., “Differential antagonisms of anticonvulsants to various components of maximal seizures induced by electroshock or pentylenetetrazol in mice”, Journal of Pharmacobio-Dynamics, (1980) vol. 3, No. 10, pp.… [cited by applicant]
Masuda, Y. et al., “3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile”, Arzneimittel-Forschung (Germany), (1980) vol. 30, pp. 477-483. 20 Refs. CODEN: ARZNAD. ISSN: 0004-417… [cited by applicant]
Masuda, Y. et al., “3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: Pharmacological profile”, Japanese Journal of Pharmacology, (1979) vol. 29, No. Suppl., pp. 30P. ISSN: 0021-5198 CODEN: JJPAAZ. [cited by applicant]
Ito, T. et al., “3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: Electroencephalographic profile”, Japanese Journal of Pharmacology, (1979) vol. 29, No. Suppl., pp. 30P. ISSN: 0021-5198 CODEN: JJ… [cited by applicant]
Ritsuko Hanajima et al., “Zonisamide for Treating Parkinson's Disease”. 2020 NeuroPsychopharmacotherapy pp. 1-9. [cited by applicant]
Office Action issued Oct. 31, 2025, In Chinese Patent Application No. 202180048407.X (with Translation) (citing document 1) (16 pgs). [cited by applicant]